SD · State regulatory reference
South Dakota.
Moderate
South Dakota's telehealth framework (SDCL ch. 34-52, Telehealth Utilization by Health Care Professionals) lets a licensed provider establish a proper provider-patient relationship and prescribe via telehealth, including through a real-time audio-video initial visit, subject to the same standard of care as in-person practice. Pharmacy compounding is overseen by the South Dakota Board of Pharmacy under ARSD article 20:51, which references USP <795>/<797> compounding standards. No distinctive statewide GLP-1/semaglutide compounding ban or documented board enforcement was located — only a Board newsletter advisory about counterfeit/adverse-event GLP-1 supply risks.
Last reviewed · 2026-05-25 · verified entry
Agencies
TPC notes
Telehealth
SDCL 34-52-3 requires a proper provider-patient relationship (identity/location verification, consent, diagnosis by acceptable practice), and 34-52-5 contemplates a real-time audio-video examination prior to diagnosis/treatment, so an initial visit and prescribing can occur via synchronous audio-video; 34-52-6 bars prescribing controlled substances solely from an internet questionnaire without a proper relationship.
Compounding
503A pharmacy compounding is regulated by the South Dakota Board of Pharmacy under ARSD article 20:51 (referencing USP <795> non-sterile and <797> sterile standards); no South Dakota-specific GLP-1/semaglutide compounding prohibition was confirmed.
Sources